Spots Global Cancer Trial Database for IFM 99-02 Thalidomide in Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: IFM 99-02 Thalidomide in Myeloma
Official Title:
Study ID: NCT00222053
Conditions
Study Description
Brief Summary: Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Médecine Interne, CHU Purpan, Toulouse, , France
Médecine Interne, Hôpital Rangueil, Toulouse, , France
Rhumatologie, CHU Purpan, Toulouse, , France
Rhumatologie, CHU Rangueil, Toulouse, , France
Service d'hématologie, CHU Purpan, Toulouse, , France
Contact Details
Name: ATTAL Michel, MD
Affiliation: CHU Toulouse
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
